Eladis^®

Eladis ^® improves respiratory function and reduces the severity and frequency of respiratory tract symptoms (respiratory symptoms), including seizures coughing and choking.¹

Eladis ^{® 1}

• expands bronchi and bronchioles in the lungs, which improves respiratory function;
• it has anti-inflammatory, antitussive and anti-allergic effects;
• reduces the manifestations of bronchial spasm and inflammation in the respiratory tract;
• reduces increased mucus secretion;
• It inhibits the release of biologically active substances (mediators) that cause inflammation and allergies and reduces the susceptibility (reactivity) of the respiratory tract to their action.

Eladis ^® has confirmed its effectiveness in clinical trials and demonstrated the following results²:

• reducing the time to clinical cure of cough by 2 days;
• reduction in the frequency of coughing attacks by 50% or more
• reduction of cough severity by more than 3.5 points by the 5th day of treatment;
• reducing the severity of SARS symptoms: general fatigue, sore throat, nasal congestion, rhinorrhea, myalgia, headache.

Recommended dose: for adults over 18 years of age, 1 tablet (40 mg) 2 times a day. The recommended duration of treatment is 7 days. If symptoms persist after 7 days of therapy, it is possible to continue treatment for another 7 days.¹

¹ OHLP of the drug Eladis ^® LP-No.=(002980)-(RG-RU) from 02/07/2024
² Clinical trial report: "A double-blind placebo-controlled multicenter randomized clinical trial to evaluate the efficacy and safety of HC8, film-coated tablets, 40 mg (JSC "Valenta Pharm", Russia) in patients with dry unproductive cough on the background of acute respiratory viral infection." Phase: III.